• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value

    4/22/25 8:00:00 AM ET
    $OCEA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCEA alert in real time by email

    Strategic diversification into power infrastructure and cryptocurrencies supports long-term biopharma innovation

    PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company focused on pioneering treatments for cancer, infectious diseases, and fibrosis, today announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana.

    This move comes as part of a deliberate plan to strengthen Ocean Biomedical's financial foundation and enhance long-term value creation for shareholders. The Company will leverage its leadership team's experience and strategic partnerships to pursue high-growth opportunities in the power and digital asset sectors—two industries central to global innovation and economic infrastructure.

    "While we remain deeply committed to advancing our scientific pipeline, we recognize the need to build stable and recurring cash flow to sustain and accelerate our biopharma mission," said Chirinjeev Kathuria, Chairman of Ocean Biomedical. "The global demand for energy—driven by AI, data centers, and digital infrastructure—is unprecedented, and cryptocurrencies have emerged as powerful stores of value with institutional and governmental recognition. These sectors represent meaningful growth vectors and give us the ability to fund our innovations with greater independence and resilience."

    Strategic Rationale for Expansion

    After an extensive strategic review, the Company identified power generation and digital assets as synergistic verticals where existing board and management expertise and market access can be swiftly mobilized. Ocean Biomedical intends to:

    • Develop and operate select power assets to capitalize on rising energy demand, with an initial focus on data center-grade infrastructure and grid-interactive generation.
    • Adopt a digital treasury model, allocating a portion of cash reserves into established cryptocurrencies such as Bitcoin and Solana, which the Company views as long-term hedges and potentially accretive assets.

    Forward-Looking Growth Objectives

    Ocean Biomedical plans to release additional details in the coming months regarding:

    • The scale, location, and technology profile of its initial power projects.
    • A defined framework for cryptocurrency holdings, including governance, custody, and rebalancing mechanisms.
    • Strategic alliances or capital partnerships that support execution in these new verticals.

    About Ocean Biomedical

    Ocean Biomedical (NASDAQ:OCEA) is a mission-driven innovation company focused on the discovery and commercialization of breakthrough therapies in oncology, infectious diseases, and fibrosis. The Company is now strategically diversifying its operations into high-growth sectors—such as energy and digital assets—to build sustainable cash flow and support the advancement of its scientific platform. Learn more at www.oceanbiomedical.com.

    Investor & Media Contacts

    Investor Relations

    [email protected]

    Media Inquiries

    [email protected]

    Forward-Looking Statements

    The information included herein and in any oral statements made in connection herewith include "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.

    Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

    Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.



    Primary Logo

    Get the next $OCEA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCEA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OCEA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocean Biomedical Expands into Energy and Digital Asset Sectors to Accelerate Growth and Shareholder Value

      Strategic diversification into power infrastructure and cryptocurrencies supports long-term biopharma innovation PROVIDENCE, R.I., April 22, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company focused on pioneering treatments for cancer, infectious diseases, and fibrosis, today announced a strategic expansion of its business operations to include power infrastructure development and a cryptocurrency treasury strategy, including Bitcoin and Solana. This move comes as part of a deliberate plan to strengthen Ocean Biomedical's financial foundation and enhance long-term value creation for shareholders. The Company will leverage its leadership team's exp

      4/22/25 8:00:00 AM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

      PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic a

      3/28/25 8:30:00 AM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

      Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) today announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean's immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper's findings demonstrate that its proprietary cancer immunothe

      2/10/25 8:00:00 AM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCEA
    SEC Filings

    See more
    • Ocean Biomedical Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - Ocean Biomedical, Inc. (0001869974) (Filer)

      6/13/25 5:25:11 PM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ocean Biomedical Inc.

      10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)

      5/15/25 5:22:58 PM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Ocean Biomedical Inc.

      10-K/A - Ocean Biomedical, Inc. (0001869974) (Filer)

      4/29/25 4:45:09 PM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Poseidon Bio, Llc claimed ownership of 22,842,756 shares

      3 - Ocean Biomedical Holdings, Inc. (0001836612) (Issuer)

      2/16/23 9:40:15 PM ET
      $OCEA
      Biotechnology: Pharmaceutical Preparations
      Health Care